Ucsf Aids Crs (801)
Welcome,         Profile    Billing    Logout  
 5 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Havlir, Diane
NCT05549726: SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

Active, not recruiting
4
984
RoW
Cabotegravir Injectable Suspension, Dynamic Choice Delivery Model, Standard of Care
University of California, San Francisco, Infectious Diseases Research Collaboration, Uganda, Makerere University, Kenya Medical Research Institute, University of California, Berkeley, National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Heart, Lung, and Blood Institute (NHLBI), ViiV Healthcare, University of Pittsburgh
HIV
12/23
01/25
NCT03848728: Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa

Completed
N/A
1988
RoW
SEARCH Youth combination intervention
University of California, San Francisco, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Infectious Diseases Research Collaboration, Uganda, Kenya Medical Research Institute, Makerere University
HIV
06/23
06/23
SEARCH-IPT, NCT03315962: Simplified Isoniazid Preventive Therapy Strategy to Reduce TB Burden

Completed
N/A
468
RoW
SPIRIT Intervention
University of California, San Francisco, Makerere University, National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Tuberculosis, HIV/AIDS
11/23
11/23
SAPPHIRE, NCT04810650: SEARCH Phase A: A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa

Completed
N/A
2233
RoW
Mobility Dynamic Treatment Intervention, Health Living Intervention for Heavy Alcohol Users, Hypertension Linkage, PrEP/PEP at Outpatient Clinics, PrEP/PEP at Antenatal Clinics, PrEP/PEP at Community Households, Standard of Care, Hypertension Community
University of California, San Francisco, Infectious Diseases Research Collaboration, Uganda, Makerere University, Kenya Medical Research Institute, University of California, Berkeley, University College, London, University of Pennsylvania, National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Heart, Lung, and Blood Institute (NHLBI)
HIV, Hypertension, Alcohol Drinking, Maternal Child Health, Cost Effectiveness
10/23
10/23
NCT05768763: SEARCH SAPPHIRE Phase B

Recruiting
N/A
80000
RoW
Community-enhanced reach activities, Person-centered care delivery, Data system enhancement to improve reach and person-centered delivery, Standard of Care
University of California, San Francisco, Infectious Diseases Research Collaboration, Uganda, Makerere University, Kenya Medical Research Institute, University of California, Berkeley, National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Heart, Lung, and Blood Institute (NHLBI), University College, London
HIV
03/26
03/26
Dwyer, Jay
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Active, not recruiting
3
310
US
Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
11/24
08/26
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Recruiting
2
48
US, RoW
Selgantolimod, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV Infections
11/26
05/27
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
NCT03705169: Pharmacokinetics and Safety of SAR441236

Terminated
1
52
US
SAR441236, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics
HIV-1-infection
04/22
04/22
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

Not yet recruiting
1
30
US
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI)
HIV-1
10/26
08/27
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Recruiting
1
46
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
06/26
12/26
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing

Recruiting
N/A
30000
US
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/27
12/27
NCT05985642: Observational PIC Destination Cohort

Recruiting
N/A
30
US
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
07/29
09/29

Download Options